SHINE Technologies Completes Acquisition of Lantheus SPECT Business

Telix Pharmaceuticals to Acquire ITM Isotope Technologies Munich

September 21, 2026

Pharmaceuticals

Telix Pharmaceuticals signed an agreement to acquire 100% of ITM Isotope Technologies Munich for $1.65 billion upfront, plus up to $700 million in contingent payments tied primarily to regulatory approvals and sales milestones for ITM-11. The deal combines Telix’s radiopharmaceutical development and commercial platform with ITM’s isotope manufacturing, distribution network, and therapeutic pipeline; it remains subject to shareholder and regulatory approvals.

Shimadzu Acquires TESCAN For $711 Million To Expand Electron Microscopy Business

July 13, 2026

Industrial Services

Shimadzu Corporation completed its acquisition of TESCAN GROUP (via acquisition of all shares of Glass HoldCo, which indirectly owns TESCAN) for $711 million. The deal expands Shimadzu’s electron microscopy and analytical instruments capabilities and supports a strategy to deliver more comprehensive, end-to-end analytical workflows across semiconductor, life sciences, and advanced materials research.

Lantheus Acquires Life Molecular Imaging (Life Molecular) for $350M Upfront

July 22, 2025

Healthcare Services

Lantheus Holdings completed its previously announced acquisition of Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings Ltd. The deal includes an upfront payment of $350 million and (per the earlier definitive agreement) up to $400 million in potential earn-out and milestone payments, and strengthens Lantheus’s commercial and R&D capabilities in Alzheimer’s PET diagnostics with Neuraceq (florbetaben F18).

Lantheus Holdings to Acquire Evergreen Theragnostics for $250 Million Upfront

January 28, 2025

Healthcare Services

Lantheus Holdings has signed a definitive agreement to acquire Evergreen Theragnostics in an all-cash deal with a $250 million upfront payment and up to $752.5 million in development and sales milestones. The acquisition is intended to expand Lantheus into a fully integrated radiopharmaceutical leader by adding Evergreen’s radiopharmaceutical CDMO manufacturing infrastructure and development capabilities, as well as the registrational-stage PET diagnostic agent OCTEVY.

Bruker Corporation Acquires Spectral Instruments Imaging

February 6, 2024

Medical Devices

Bruker Corporation has acquired Spectral Instruments Imaging LLC, a Tucson-based maker of preclinical in‑vivo optical imaging systems, to broaden Bruker BioSpin's preclinical imaging portfolio. Financial terms were not disclosed; SII generated over $10 million in revenue in 2023 and will expand Bruker's capabilities in bioluminescence, fluorescence and X‑ray preclinical imaging.

Lantheus Holdings Acquires Cerveau Technologies

February 6, 2023

Pharmaceuticals

Lantheus Holdings, Inc. acquired Knoxville-based Cerveau Technologies, Inc., gaining MK-6240, a clinical-stage F-18 PET imaging agent that targets Tau tangles in Alzheimer's disease. The stock purchase includes upfront and potential milestone payments plus royalty obligations and will expand Lantheus' radiopharmaceutical diagnostic imaging pipeline and research collaborations.